Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial.

doi:10.1007/s10549-026-07985-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial.

Breast cancer research and treatment - 1 Jun 2026

Lee Kamaria L, Yam Clinton, Zhao Li, Bassett Roland L, Song Xingzhi, Thompson Alastair M, White Jason B, Layman Rachel M, Huo Lei, Gutierrez Angelica M, Valero Vicente, Ueno Naoto T, Litton Jennifer K, Zhang Jianhua, Ravenberg Elizabeth, Korkut Anil, Adrada Beatriz E, Candelaria Rosalind P, Rauch Gaiane M, Tripathy Debu, Shaitelman Simona F, Arun Banu K

Abstract excerpt

PURPOSE: Most patients with triple-negative breast cancer (TNBC) undergo neoadjuvant therapy (NAT). Prospective studies on the landscape of non-BRCA germline pathogenic variants (PVs) in patients with TNBC and their impact on response to NAT are sparse. METHODS: On a prospective trial, patients received NAT with doxorubicin and cyclophosphamide with or without immunotherapy followed by paclitaxel with or without...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cyclophosphamide

Share to Genetic Predisposition to Disease

Share to Germ-Line Mutation

Share to Neoadjuvant Therapy

Share to Treatment Outcome

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42223695
DOI: 10.1007/s10549-026-07985-7
PMCID: PMC13226415

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial.PMID 42223695Read ↗

Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.Semantic proximity Read ↗

Assessing germline mutational profile and its clinicopathological associations in Triple Negative Breast CancerSemantic proximity Read ↗

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast CancerSemantic proximity Read ↗

Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer.Semantic proximity Read ↗

Germline Mutations Related to Complete Remission after Neoadjuvant Chemotherapy in Patients with Triple-negative Breast CancerSemantic proximity Read ↗

Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.Semantic proximity Read ↗

Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational statusSemantic proximity Read ↗

Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple Negative Breast CancerSemantic proximity Read ↗

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.Semantic proximity Read ↗

Germline Mutations in Triple-Negative Breast CancerSemantic proximity Read ↗

Somatic mutations of triple-negative breast cancer: a comparison between Black and White women.Semantic proximity Read ↗

The Impact of Germline BRCA Mutations in Locally Advanced, Triple Negative Breast Cancer Treated with Platinum Based Neoadjuvant ChemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.